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ABSTRACT
ASSESSING THE PREVALENCE OF ANEMIA POST COVID-19 INFECTION IN ADULT MEMBERS OF A
SOUTHEASTERN INTEGRATED HEALTHCARE SYSTEM
By
ALEXANDER F. HUDGINS IV
May 20th, 2022
INTRODUCTION: Since the SARS-CoV-2 emergence in 2019, the subsequent disease COVID-19 has
become a global public health emergency. While substantial research has been done regarding the
acute phase of this disease, little is known about the long-term health implications of COVID-19,
including the biological mechanisms leading to the development of persistent symptoms following
infection known as “long-COVID”. One suggested causal pathway is that the immune response induced
by SARS-CoV-2 causes dysregulation of iron homeostasis, hemolysis, and/or erythropoiesis, resulting in
abnormally low Hgb levels and insufficient O2 transfer. Developing a better understanding of these
mechanisms is key to treating and preventing the long-term health implications linked to COVID-19.
AIM: The aim of this study is to evaluate the prevalence of anemia 180-days post-COVID diagnosis and
assess potential risk factors including patient demographics, comorbidities, and hospitalization (COVID
severity) status.
METHODS: The sample was obtained from KPGA’s CURE Cohort and EMR. Individuals aged ≥18 at
COVID-19 diagnosis, alive as of February 2022, and with Hgb labs taken pre- and 180-days post- COVID19 diagnosis ±30-days were included in the study. Anemia was defined as blood hemoglobin (Hgb) levels
<12.0g/dL for females and <13.0g/dL for males. Unadjusted univariate and adjusted multivariable
logistic regression were used to calculate odds ratios and assess the association between anemia and
exposures of interest.
RESULTS: We found the prevalence of anemia at 180-days post-COVID to be 34.1%. Univariate analysis
showed that age (≥65) (OR=1.40, 95% CI: 1.00, 1.97), Black/African American race (OR=2.46, 95% CI:
1.98, 3.05), obesity (OR=1.33 95% CI: 1.08, 1.64), kidney disease (OR=2.48, 95% CI: 1.91, 3.22), diabetes
(OR=2.14, 95% CI: 1.72, 2.68), hypertension (OR=1.44, 95% CI: 1.16, 1.78), malignant cancer (OR=1.70,
95% CI: 1.28, 2.27), heart disease (OR=1.55, 95% CI: 1.25, 1.93), hospitalization (COVID-severity)
(OR=2.46, 95% CI: 1.89, 3.21), and pre-COVID anemia (OR=13.71, 95% CI: 10.57, 17.77) were significantly
associated with post-COVID anemia. The final fitted multivariable logistic regression model showed that
Black/African American race (OR=1.74, 95% CI: 1.34, 2.26), diabetes (OR=1.53, 95% CI: 1.14, 2.05),
malignant cancer (OR=1.47, 95% CI: 1.02, 2.13), hospitalization (COVID-severity) (OR=1.92, 95% CI: 1.37,
2.70), and pre-COVID anemia (OR=11.58, 95%CI: 8.85, 15.17) were significantly associated with postCOVID anemia. In a sensitivity analysis using our final fitted multivariable logistic regression,
hospitalization was treated as an effect modifier. Among individuals not hospitalized for COVID-19,
Black/African American race (OR=2.03, 95% CI:1.52, 2.72) was significantly associated with increased risk
of having post-COVID anemia.
DISCUSSION: The findings of this study show that individuals diagnosed with diabetes, cancer, and
anemia pre-COVID are at increased risk of post-COVID anemia. Additionally, individuals identifying as
Black or African American had significantly higher risk of post-COVID anemia, specifically in the
outpatient (non-severe COVID-19) population. There was significant overlap with post-COVID anemia
risk factors identified in both the adjusted/unadjusted analysis and known risk factors for long-COVID.
Future research should look to further examine the causal link between anemic Hgb levels post-COVID
infection and the development of long-COVID.
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Chapter 1
Introduction
1.1: Background:
In December 2019, a large cluster of unexplained respiratory illnesses in Wuhan China
led to the discovery of the novel coronavirus severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) (Harrison et al., 2020; Mohamed Khosroshah et al., 2021; Amawi et al., 2020; Yuki
et al., 2020; Giamarellos-Bourboulis et al., 2020). SARS-CoV-2 infection leads to a respiratory
disease called COVID-19. Since its emergence, COVID-19 has become one of the largest public
health problems in recent history with the WHO declaring it to be a pandemic and a “public
health emergency of international concern” (Mohamed Khosroshah et al., 2021). As of February
2020, the WHO reported that there have been over 400 million cases and 5.7 million deaths
(WHO, 2020).
In individuals infected with COVID-19, symptoms and disease severity range from mild
to severe, developing 4-5 days after exposure with mild infections resolving 7-10 days after
onset (Raveendran et al., 2021). Disease progression into severe cases is marked by extreme
respiratory distress and multiple organ dysfunction leading to high risk of mortality. In those
that recover from acute COVID-19 infection, many have persistent symptoms or heath issues
remaining months after infection. It is estimated that over one third of all COVID patients and
87% of hospitalized patients will have persistent symptoms termed “long-COVID” or “postCOVID syndrome” (Raveendran et al., 2021).
While much about the novel SARS-CoV-2 and subsequent COVID-19 disease is still not
fully understood, research suggests that massive inflammatory response and immune
dysregulation is the driving force behind respiratory distress and multiple organ
involvement/damage (Mohamed Khosroshah et al., 2021). Long-COVID has been shown to
include multiple organ systems suggesting that lingering inflammation may play a role (Yan et
al., 2021). One proposed mechanism for how inflammation causes this multiple organ
involvement is through the disruption of red blood cells (RBCs) (Taneri et al., 2020). The
inflammatory response to SARS-CoV-2 causes dysregulation of iron homeostasis, hemolysis,
1

and/or erythropoiesis, resulting in abnormally low hemoglobin (Hgb) levels and the
development of anemia of inflammation (Bergamaschi et al., 2021). Reduced RBC count and
subsequent Hgb levels reduces the amount of oxygen that can be transported to the body’s
tissues (WHO, 2019). This insufficient O2 transfer leads to multiple organ injury and further
progression of COVID-19 (Taneri et al., 2020).
1.2: Purpose:
Most COVID-19 research has focused on the acute phase of COVID-19 infections
typically ranging from 7 to 14 days after infection. Research focusing on long-COVID typically
defined as persistent symptoms in the weeks or months following initial recovery, has almost
entirely been on hospitalized patients. Research into how mechanisms of disease severity differ
in the entire population is needed, specifically looking at how levels of markers like Hgb change
post-infection to identify possible abnormalities that could lead to the persistent symptoms
seen in long-COVID. This study attempts to do just that, investigating the prevalence of anemia
post-COVID infection. The prevalence of anemia will be compared among hospitalized and nonhospitalized patients. The role of other possible risk factors such as age, sex, race, and various
comorbidities will be assessed to provide a more comprehensive picture of anemia risk postCOVID infection. Hopefully the findings of this research will shed light on possible risk factors
and mechanisms for the development of long-COVID.
1.3: Research Questions:
1.3.1: Research Question #1
Among adult (18+) members of a southeastern integrated healthcare system, is there an
association between patient demographics characteristics (age, sex, and race) and risk of
anemia post-COVID infection?
1.3.2: Research Question #2
Among adult (18+) members of a southeastern integrated healthcare system, is there an
association between diagnosed comorbidities (smoking, obesity, rheumatologic diseases,
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kidney disease, liver disease, COPD, diabetes, hypertension, hypothyroidism, malignant cancer,
and heart disease) and risk of anemia post-COVID infection?
1.3.3: Research Question #3
Among adult (18+) members of a southeastern integrated healthcare system, is there an
association between post-COVID anemia and COVID-19 infection severity measured by
hospitalization status (inpatient vs outpatient treatment)?

3

Chapter 2
Literature Review
The majority of research conducted around COVID-19 has regarded its acute symptoms
and short-term outcomes. However, more recent research has started to evaluate the longterm implications of COVID-19 infections in both severe and moderate cases of the disease. This
literature review provides a summary of the current research findings and our understanding of
the SARS-CoV-2 virus and subsequent COVID-19 infection. The review also examines anemia
characterized by low Hgb levels and the role it plays in the prognosis of COVID-19, establishing
the basis of inclusion for the variables of interest in this study.
2.1: SARS-CoV-2 and COVID-19
2.1.1: SARS-CoV-2
In December 2019, unexplained cases of pneumonia were identified in Wuhan China,
leading to the discovery of the novel coronavirus severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) in January 2020 (Amawi et al., 2020). Classified as a β
coronaviruses, it is very similar to MERS-CoV and SARS-CoV (Yuki et al., 2020; Salian et al., 2021;
Amawi et al., 2020; Sanyal, 2020), sharing 50% and 80% genome sequence with MERS-CoV and
SARS-CoV respectively (Harrison et al., 2020). Like its counterparts, SARS-CoV-2 attacks the
respiratory system leading to a disease known as COVID-19. However, it has unique putative
short proteins that increase its ability to replicate and transmit viral proteins (Salian et al.,
2021), making SARS-CoV-2 more transmissible than its counterparts above and resulting in its
rapid spread around the globe and the current pandemic we find ourselves in.
As the pandemic has progressed, we have gained a better understanding of the
transmission routes and mechanisms of SARS-CoV-2 infection. It is now understood that the
virus is transmitted person to person via droplets and/or aerosols (Salian et al., 2021; Amawi et
al., 2020). Infected individuals both symptomatic and asymptomatic release the droplets into
the air by coughing, sneezing, normal breathing, and speech (Salian et al., 2021; Harrison et al.,
2020). Individuals can become infected by breathing in these droplets or coming into contact
4

with contaminated surfaces. The virus then enters the body through the nasal and larynx
mucosa making its way to the lungs via the respiratory tract (Sanyal, 2020). Once in the lungs
SARS-CoV-2 enters the peripheral blood and can spread throughout the body (Sanyal, 2020).
SARS-CoV-2 infects the body by using the receptor angiotensin-converting enzyme 2
(ACE2) to enter and replicate in the cells of the lungs, bronchus, gastrointestinal tract, heart,
kidneys, oral and nasal mucosae (Amawi et al., 2020; Sieck, 2020; Salian et al., 2021; Sanyal,
2020) causing an inflammatory response by the hosts immune system (Sieck, 2020) and
affecting not only the respiratory system but other organ systems such as the cardiovascular,
GI, renal, and neurological systems (Yuki et al., 2020). The spread of the virus throughout the
body’s organ systems combined with a dysregulated immune response leads to progression of
the disease COVID-19 (Sanyal, 2020).
2.1.2: COVID-19 Acute Phase
Once exposed to SARS-CoV-2 it takes an estimated 2-14 days to develop COVID-19 (CDC,
2021). The symptoms and outcomes of COVID-19 can be mild, moderate, or severe. The most
common symptoms of mild and moderate disease are cough, fever, fatigue, myalgias, dyspnea,
loss of smell and loss of taste (Salian et al., 2021; Amawi et al., 2020; Yuki et al., 2020). With
more severe forms of the disease, the major clinical manifestation is pneumonia caused by lung
damage ranging from mild to severe. The most severe cases lead to “acute respiratory distress
syndrome” (ARDS) causing low blood O2 saturation and hypoxemia representing a significant
risk of mortality (Mohamed Khosroshah et al., 2021). In addition to the respiratory system,
COVID-19 has been shown to impact multiple organ system throughout the body which can
lead to multiple organ dysfunction and death in severe cases. The cardiovascular, neurological,
gastrointestinal, and renal systems have also been shown to be impacted by COVID-19
(Mohamed Khosroshah et al., 2021; Salian et al., 2021).
The range of disease severity may be quite heterogeneous; however, current research
has provided a strong fundamental basis of who is at risk for more severe outcomes. Older (age
≥ 65), immunosuppressed and individuals with comorbidities such as cardiovascular disease
(CVD), hypertension, diabetes, and chronic lung disease are at increased risk for worse
5

outcomes related to COVID-19 (Salian et al., 2021; Mohamed Khosroshah et al., 2021; Yuki et
al., 2020). This includes hospitalization, ventilation, acute respiratory distress syndrome (ARDS),
multiple organ failure, and death.
While much about the pathophysiology of COVID-19 is still poorly understood, several
studies indicate that immune alteration leading to immune dysregulation are likely to be the
core pathogenic element of COVID-19 and the driving cause of organ/tissue damage (Mohamed
Khosroshah et al., 2021). Immune dysregulation is the body’s inability to properly govern its
immune response; in COVID-19 this is caused by an ineffective innate immune response
compensated for by an over-activation of immune cells (Giamarellos-Bourboulis et al., 2020;
Tahaghoghi-Hajghorbani et al., 2020). This notion is supported by the abnormal blood cell
counts found in patients showing leukocytosis, lymphopenia, and enhanced neutrophil-tolymphocyte ratio (NLR) has been associated with disease severity and worse outcomes (Tjendra
et al., 2020; Velavan & Meyer, 2020). Abnormally low Hgb levels and consequently reduced
oxygen transfer to the body’s organ systems has been proposed as a possible mechanism for
the immune dysregulation and the organ/tissue damage we see in severe COVID-19 patients.
2.1.3: Post-COVID Syndrome
Post-COVID Syndrome also known as “long-COVID” is a term created to define the
phenomena of persistent symptoms following acute COVID-19 infection. The World Health
Organization (WHO) defines it as a condition that “occurs in individuals with a history of
probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with
symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis”
(Soriano et al., 2021). It has been shown to impact individuals across the entire scope of acute
COVID-19 severity from mild to severe (Di Toro et al., 2021). It is estimated that one third of all
those infected with COVID-19 will develop or have persistent symptoms post COVID-19 (Crook
et al., 2021). However, those hospitalized are at significantly higher risk with an estimated 35%
and 87% prevalence of long-COVID among outpatient and hospitalized individuals respectively
(Raveendran et al., 2021). Additionally older individuals, females, those with an increased
number of symptoms in the acute phase and comorbidities like hypertension, obesity,
6

psychiatric conditions, and immunosuppressive conditions have higher risk for long-COVID
(Crook et al., 2021; Mandal et al., 2020; Raveendran et al., 2021).
The symptoms experienced post-COVID infection vary and involve numerous organ
systems. The most common symptoms experienced are fatigue, dyspnea, myalgia, headache,
cognitive impairment, and sleep disturbances (Di Toro et al., 2021; Crook et al., 2021; Yan et al.,
2021). In hospitalized patients, it is estimated that over 50% experience fatigue, over 50%
experience dyspnea, and 44.1% report worsened quality of life (Raveendran et al., 2021;
Mandal et al., 2020). Abnormal levels of specific biomarkers have also been observed in
patients post-COVID infection signaling multiple organ system involvement and continued
inflammatory response. Almost all research on these markers has been conducted in
hospitalized patients. However, in individuals post hospitalization we see abnormal d-dime, Creactive protein, and blood cell counts (Mandal et al., 2020).
Long-COVID has been shown to impact multiple organ systems including the respiratory,
cardiovascular, hematological, renal, digestive, neurological, musculoskeletal, and metabolic
systems (Yan et al., 2021). A retrospective cohort study found that individuals who had been
hospitalized for COVID were significantly more likely to develop respiratory disease, diabetes,
and cardiovascular disease compared to controls (Ayoubkhani et al., 2021). There are many
possible mechanisms for the post-COVID impact on the various organ systems. Some of the
most common and recurring are chronic lasting inflammatory response, impaired oxygen
supply, excessive ACE2 receptor expression, blood vessel and lung damage (Yan et al., 2021;
Crook et al., 2021).
We still do not have a concrete understanding of the mechanisms behind the multiple
organ involvement causing post-COVID infection. Expanding our understanding of the causative
processes of this disease across the entire spectrum of COVID-19 severity is key in improving
long term outcomes. One proposed mechanism for this multiple organ involvement is
insufficient blood oxygen transfer to the body’s tissues; Hgb is the mechanism for this transfer
and thus abnormally low Hgb levels could be a driving force in the multiple organ dysfunction
seen in COVID-19 (Taneri et al., 2020; Hariyanto & Kurniawan, 2020). This notion is further
7

supported by the fact that both the body’s inflammatory immune response and SARS-CoV-2’s
interaction with host cells have been shown to dysregulate RBC’s production and life cycle
resulting in reduced Hgb levels in infected individuals (Cavezzi et al., 2020; Bergamaschi et al.,
2021; Faghih Dinevari et al., 2021; Fouad et al., 2021).
2.2: Anemia
Hgb is an iron-rich protein in red blood cells (RBC) that transports oxygen from the lungs
to the body’s tissues and organ systems. Anemia is a condition in which the total number of
RBC or Hgb concentration in the body is insufficient to meet the body’s physiological need for
oxygen (Chaparro & Suchdev, 2019; WHO, 2019). Anemia is most commonly diagnosed by lab
values for the Hgb concentration in an individual’s blood. The WHO set the diagnostic criteria
for anemia as Hgb concentrations less than 13.0g/dL (8.0mmol/L) for adult men and less than
12.0g/dL (7.5mmol/L) for adult, non-pregnant women (Wouters et al., 2018). The lack of
oxygen transmission induces a wide range of clinical symptoms, the most common of which
are: fatigue, dizziness, shortness of breath, fast or irregular heartbeat, cold hands or feet, and
palmar pallor (Chaparro & Suchdev, 2019; WHO, 2019; American Society of Hematology, 2022).
2.2.1: Classifications of Anemia
Anemia is caused by an imbalance of erythrocyte loss compared to production caused
by insufficient production of RBCs and/or an excessive loss of RBCs. The former is typically due
to nutritional deficiencies, or inflammation; the latter is typically caused by blood loss and/or
hemolysis (Chaparro & Suchdev, 2019). There are several biological mechanisms leading to the
development of anemia. They are commonly used to classify anemia into diagnostic types. In
this section of the review, we will examine the two most prevalent classifications, anemia of
inflammation and iron deficiency anemia.
Iron is one of the key components in creating Hgb and RBCs. Iron deficiency anemia
(IDA) occurs when concentrations of iron in the body are insufficient to meet the body’s
demand for RBC production or maintenance (Chaparro & Suchdev, 2019). This can be the result
of insufficient iron intake, increased iron loss, or inadequate iron absorption. IDA can be
diagnosed by the body’s iron concentration; assessed by an individual’s serum ferritin and
8

soluble transferrin receptor (sTfR) levels. Low serum ferritin and elevated sTfR levels indicate
IDA (Chaparro & Suchdev, 2019). However, IDA can be difficult to diagnose as the acute
immune response and inflammation can influence levels of these biomarkers (Chaparro &
Suchdev, 2019).
Anemia of inflammation (AI) also known as anemia of infections is caused the body’s
inflammatory immune response to defend it from pathogens. The immune response triggers
the release of proinflammatory cytokines (particularly IL-6) which alter iron metabolism by not
allowing iron stored with in the cells of the liver, spleen, and intestinal enterocytes to be
released (Chaparro & Suchdev, 2019). This subsequently reduces the body’s ability to produce
and the life span of RBCs (Chaparro & Suchdev, 2019). This type of anemia is the second most
prevalent form behind iron deficiency.
2.2.2: Risk Factors of Anemia
There are several important factors that increase the risk of developing anemia
including: sex, age, race, comorbidities, and lifestyle factors. Females, specifically women of
reproductive age, are at an increased risk of developing anemia due to the fact that
menstruation can decrease iron stores and increased blood production during pregnancy can
outpace the body’s iron supply (American Society of Hematology, 2022; Chaparro & Suchdev,
2019).
Age is another important predictor of anemia risk, as Hgb levels change significantly
throughout our lifetime based on developmental stages with the lowest Hgb levels being found
at the two ends of the spectrum during infancy and older adulthood (Chaparro & Suchdev,
2019). This puts young children and older adults at increased risk of anemia. It is also important
to note that the interaction between age and anemia is influenced by gender. Female’s risk of
anemia decreases from childhood to puberty then increases during reproductive years followed
by a decrease after menopause then increases into older adulthood (Wouters et al., 2018;
Chaparro & Suchdev, 2019). Risk of anemia in women has been shown to peak in the 40-49 and
80-85 year old age groups (Le, 2016). Male’s risk of anemia decreases from infancy to
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adolescence, levels off during adulthood and then increases into older adulthood (Wouters et
al., 2018; Chaparro & Suchdev, 2019).
Race also impacts anemia risk; individuals of African descent and those identifying as
non-Hispanic Blacks have been shown to have lower Hgb levels and higher risk of anemia
compared to White individuals (Chaparro & Suchdev, 2019; Gonzalez-Velez et al., 2020; Le,
2016). This can be partially accounted for by the fact that genetic Hgb disorders such as sickle
cell anemia are more prevalent in individuals of African descent (Chaparro & Suchdev, 2019).
However, recent research suggests that social determinates of health may play just as an
important role (Weyand et al., 2021). A study of NHANES data from 2003-2012 found that for all
age groups and sexes, non-Hispanic Blacks had the highest prevalence of anemia (Le, 2016).
When compared to non-Hispanic Whites, the prevalence of anemia was significantly higher in
non-Hispanic Blacks. This association was seen in both males and females (Le, 2016). This
association is further shown by another study on 197,974 individuals finding that African
Americans had a significantly higher prevalence of anemia (p<0.001) (Gonzalez-Velez et al.,
2020). Regardless of the causal pathway, current literature suggests that African Americans are
at increased risk of developing anemia (Chaparro & Suchdev, 2019; Gonzalez-Velez et al., 2020;
Le, 2016; Weyand et al., 2021).
Comorbidities of chronic conditions such as rheumatoid arthritis or other autoimmune
disease, kidney disease, cancer, liver disease, HIV, tuberculosis, thyroid disease, inflammatory
bowel disease (Crohn disease or ulcerative colitis), and obesity have been shown to increase
one’s risk of anemia (Chaparro & Suchdev, 2019; American Society of Hematology, 2022). These
chronic conditions lead to prolonged chronic inflammation which in turn can decrease RBC
production and efficacy leading to an increased risk of anemia (Cappellini et al., 2019).
Additionally, many reduce the body’s ability to intake and absorbed iron, the key building block
of RBCs and Hgb, further increasing the risk of anemia (Cappellini et al., 2019).
Additionally, lifestyle and socio-economic factors like smoking, multiple drug use,
education level, income, and living situation have been shown to play a role (Wouters et al.,
2018). One study found that smoking, sleeping less than 6 hours per night, and performing less
10

than 2 hours of physical activity per week were significantly associated with increased risk of
anemia (Paramastri et al., 2021). Education level and socioeconomic status have also been tied
to risk of anemia. With those of lower education and income level being at increased risk for
developing anemia, this risk is heightened for pregnant women and young children (Abdo et al.,
2019; Lee et al., 2014). One causal link between socioeconomic status and anemia is the
availability and affordability of nutrient rich foods (Lee et al., 2014). Due to the surrounding
infrastructure, socially and economically disadvantaged populations are at higher risk of living
in food deserts, placing them at even higher risk as diets high in meats, sugary beverages, fried
and processed foods have been shown to increase the risk of anemia (Paramastri et al., 2021).
Due to the numerous risk factors and multiple mechanisms of development, the etiology of
anemia is very complex and further research is needed to fully understand the role infectious
and chronic diseases play.
2.2.3: Health Outcomes Related to Anemia
One of the most significant health risks of anemia is its impact on child and maternal
health. This in large part is due to the increased risk these groups are under as well as the key
developmental stage they are in. Anemia has been shown by numerous studies to increase the
risk of maternal, neonatal, perinatal and child mortality (WHO, 2019). Additionally, it is
associated with negative health and developmental outcomes among infants and children,
including premature birth, low birth weight, impaired neurological and delayed child
development (Chaparro & Suchdev, 2019). The impact that anemia has on child health and
development is due to the impacts of decreased oxygen delivery to tissues during fundamental
formative stages of development.
Additionally, individuals with anemia have been shown to have significantly lower health
related quality of life (Chaparro & Suchdev, 2019; Wouters et al., 2018). The prevalence of even
mild anemia in older individuals is associated with decreased physical performance, increased
risk of falls and more frequent hospital stays (Wouters et al., 2018). This decrease in quality of
life may be more significant in older individuals but the association holds true across all age
groups. Wouters et al. (2018) conducted retrospective cohort study on 138,670 subjects, aged
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18-93 years and compared survival and health related quality of life between anemic and nonanemic individuals. They found anemia was significantly associated with health-related quality
of life across all age groups with the most significant differences being found among those 60years or older. After accounting for potential confounders and effect modifiers in a multiple
logistic regression, anemia was still associated with lower health related quality of life across all
age groups (OR: 1.28 95% CI: 1.00 – 1.64; P=0.046).
Anemia has been shown to increase risk for all-cause mortality (Martinsson et al., 2014;
Chaparro & Suchdev, 2019; Wouters et al., 2018). Martinsson et al. (2014) found that when
looking at the general adult population, the risk of all-cause mortality among anemic individuals
was estimated to be 2.16 times that of non-anemic individuals. They also found that cause
specific mortality for cardiovascular disease and cancer was significantly higher in anemic
individuals. Another retrospective cohort study found that in adults over the age of 60 survival
rates were significantly lower in anemic compared to non-anemic individuals (Wouters et al.,
2018). There is currently some debate over at what age anemia becomes a significant risk factor
for mortality though it is well established that in older individuals it represents a significant risk.
2.3: Anemia & COVID-19
Current literature suggests that there are multiple pathways for SARS-CoV-2 to cause
anemia in its hosts. There is general agreement that it is done in two ways: SARS-CoV-2 directly
interacting with host cells and/or through the inflammatory response of the innate immune
system induced by the virus (Tao et al., 2020; Bellmann-Weiler et al., 2020; Fouad et al., 2021;
Cavezzi et al., 2020; Bergamaschi et al., 2021). For both humans and pathogens, iron is an
essential micronutrient; during infection, the immune response may try to restrict iron
availability (Taneri et al., 2020). Therefore, the inflammatory reaction created to fight SARSCoV-2 in the body significantly impacts erythropoiesis aka the production of red blood cells. It
does so through multiple mechanisms, including abnormal iron metabolism caused by the
overproduction of interleukin (IL)-6 (Bergamaschi et al., 2021; Taneri et al., 2020; Faghih
Dinevari et al., 2021; Fouad et al., 2021) and resulting in reduction of erythrocyte life span via
the inhibitory effects of pro-inflammatory cytokines on erythroid progenitor and precursor cells
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(Bergamaschi et al., 2021; Taneri et al., 2020; Faghih Dinevari et al., 2021; Fouad et al., 2021). It
also increases the retention of iron by macrophages and decreasing absorption in the GI tract
(Fouad et al., 2021). Consequently, the circulating iron available for erythropoiesis and Hgb
production is reduced (Fouad et al., 2021) leading to anemia of inflammation.
Additionally, like all coronaviruses, SARS-CoV-2 uses its spiked protein to facilitate entry
and interaction with host cells (Cavezzi et al., 2020). The spike protein of COVID-19 has been
shown to react with ACE2 receptors on macrophages and mimic the protein hepcidin which is
the most significant regulator of iron (Cavezzi et al., 2020; Hariyanto & Kurniawan, 2020). This
mimicry results in a significant dysregulation of iron metabolism and subsequently disrupts RBC
creation, maintenance, and Hgb levels (Cavezzi et al., 2020; Hariyanto & Kurniawan, 2020)
leading to the development of anemia in the host. These two pathways most likely work in
tandem causing the high levels of anemia seen in COVID-19 patients.
2.3.1: Anemia and COVID-19 Risk Factors
Most research on anemia and COVID-19 has been conducted on hospitalized patients.
The risk factors identified in these studies may also provide a formative picture of the inherent
risk in outpatient populations as well. Hospitalized COVID-19 patients of older age and higher
number of comorbidities such as kidney disease, CVD, hypertension, COPD, diabetes, and
cancer have a significantly higher risk for developing anemia (Taneri et al., 2020; Tao et al.,
2020; Bellmann-Weiler et al., 2020; Faghih Dinevari et al., 2021). One study following both
outpatient and in-patient COVID-19 cases found similar results, showing significantly greater
risk of anemia in those with CVD, heart failure, diabetes, COPD, and chronic kidney disease
(Benoit et al., 2020). In hospitalized populations, the longer they remain hospitalized the
increased risk they have of developing anemia illustrating that Hgb levels tend to decrease as
the disease progresses (Berzuini et al., 2021). It has been estimated that between 40% and 60%
of patients hospitalized with COVID-19 develop anemia (Bergamaschi et al., 2021; BellmannWeiler et al., 2020). One study conducted during the peak of the COVID-19 outbreak in Italy
found that 39% of inpatients needed blood transfusion support with the median time from
admission to blood transfusion being 15-days (Berzuini et al., 2021.). Barriteau et al. (2020)
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found that 13.4% of inpatients required transfusion support during treatment for COVID-19,
signifying that since the start of the pandemic the need for transfusion may have decreased but
still represents a significant number of patients. These risk factors signify important variables to
consider when evaluating the relationship between COVID-19 and anemia.
2.3.2: Anemia and COVID-19 Health Outcomes
Other respiratory diseases like COVID-19 have been shown to be exacerbated by
concurrent anemia resulting in more severe outcomes and risk of mortality (Tao et al., 2020;
Fouad et al., 2021). Similar results have been seen in the evaluation of anemia’s impact on the
progression of COVID-19. Bergamaschi et al. (2021) conducted an observational study of 206
hospitalized COVID-19 patients comparing them to 71 controls negative for SARS-CoV-2 but
exhibiting similar respiratory symptoms to examine the prevalence, pathogenesis, and clinical
significance of anemia in COVID patients. They found that individuals with COVID-19 had higher
incidence of overall anemia (OR 1.88, 95% CI 1.09–3.24) as well as moderate/severe anemia
(4.16, 95% CI 1.39–15.68) compared to those with similarly presenting respiratory illness.
When examining how anemia impacts COVID-19 outcomes, multiple studies have shown
anemia is an independent risk factor for severity of COVID-19 (Tao et al., 2020; Fouad et al.,
2021; Hariyanto & Kurniawan, 2020). Tao et al. (2020) conducted a retrospective cohort study
examining the 222 hospitalized COVID-19 patients. They found that when analyzed alone the
risk of severe COVID in anemic individuals was 3.47 times that of non-anemic individuals (95%
CI: 1.02-11.75). This relationship held true after adjustment for baseline date and laboratory
indices with an estimated odds ratio of 3.77 (95% CI:1.33-10.71). Other studies have looked
deeper finding that anemia is significantly associated with hypoxia, ICU admission and risk of
mechanical ventilation (Faghih Dinevari et al., 2021; Taneri et al., 2020). Faghih Dinevari et al.
(2021) conducted a prospective study of 1,274 hospitalized patients in Iran finding that
individuals with anemia were significantly more likely to require mechanical ventilation and be
admitted to the ICU. These associations remained significant when accounting for significant
covariates, estimating that the odds ratio was 1.68 (95% CI: 1.10, 2.57) and 2.06 (95% CI: 1.46,
2.90) for ventilation and ICU admission respectively.
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The findings regarding the association between anemia and COVID-19 mortality and
survival were mixed with some studies finding it significant and others finding it did not play a
significant role. Faghih Dinevari et al. (2021) and Bellmann-Weiler et al. (2020) found that
anemia was significantly associated with mortality while Taneri et al. (2020) and Tao et al.
(2020) found that though more anemic patients died, it was not associated with mortality. The
difference in these findings could be due to differences in the study populations or the way
anemia was determined. Some studies used only labs from the time of initial hospitalization
while others took multiple labs throughout hospitalization. Hgb levels have been shown to get
lower throughout progression of the disease (Berzuini et al., 2021).
Very little research has been conducted examining how Hgb levels change post-COVID
following recovery for the acute phase and how this may impact long-COVID. However, from
the available research, results have been shown to somewhat vary which may be due to
variability in sample populations. Pasini et al. (2021) conducted a prospective cohort study
examining 75 adults hospitalized for COVID-19 who reported new symptoms of fatigue,
dyspnea, and/or muscle weakness following diagnosis. These participants were followed for 2months at which time a blood serum profile was taken. They found that after 2-months of
follow up, 87% had Hgb levels low enough to be considered clinically significant. In contrast,
Sonnweber et al. (2020) studied 109 individuals with mild to critical COVID-19, with the
majority (80%) being hospitalized cases. Sonnweber et al. evaluated prevalence of anemia 60days after the onset of COVID-19, finding that only 9.2% of patients still had anemic Hgb levels.
While most research was conduct mainly on hospitalized individuals, one study did evaluate
non-hospitalized individuals. Garg et al. (2021) retrospectively evaluated 19 individuals with
COVID-19 showing symptoms of long-COVID at least 30-days post-diagnosis. They found that
with a median follow up of 41-days, 21.1% of individuals experiencing long-COVID had anemic
Hgb levels. This research study looks to build on the current literature by expanding the followup period to 180-days and including a much larger sample size, in the hopes of providing results
which can start to better shape our understanding of how Hgb levels change post-COVID and
how it may be impacting the development of long-COVID.
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Chapter 3
Methods and Procedures
3.1: Data Source
This is a cross-sectional study using data from Kaiser Permanente Georgia’s (KPGA)
electronic medical record (EMR). The data include healthcare information from members of a
southeastern integrated healthcare system testing positive for COVID-19 between January 1,
2020, and December 31, 2021. Data was collected for individuals enrolled in the study and
included demographic, lab, hospitalization, healthcare utilization, medication, comorbidities,
and health status information. Participants were assigned a unique study ID used as their
unique identifier for this study. All data was pulled from the electronic medical record (EMR)
then cleaned and analyzed using SAS. The Kaiser Permanente Georgia, Emory University, and
Georgia State University Institutional Review Boards reviewed and approved this research
project.
3.2: Inclusion & Exclusion Criteria
All KPGA members enrolled in the CURE cohort were assessed for eligibility. This cohort
was designed to assess racial disparities among Black/African American and COVID-19 risk
factors with the secondary goal of creating a cohort to evaluate COVID-19 outcomes at 30-, 60and 90-days. It included KPGA members diagnosed with COVID-19 between January 2020 and
December 2021, both hospitalized and non-hospitalized individuals. To be included in this study
from this cohort, participants must have been diagnosed with COVID-19 (ICD-10: B34.2, B97.21,
B97.29, J12.81, and U07.1), aged ≥ 18 at the time of COVID diagnosis and have Hgb labs preand post- COVID-19 infection to assess anemia status. Pre-COVID labs must have been taken 45
days prior to COVID-19 diagnosis and post-COVID labs must have been taken at 180-days post
COVID-19 diagnosis ±30-days. Participants who died before February 22, 2022, were excluded
from this study.
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3.3: Variables of Interest
3.3.1: Anemia
Anemic status was assessed using labs results for the blood level of Hgb. The WHO
criteria of anemia defined as Hgb levels less than 12.0 g/dL for females and 13.0 g/dL for males
was used to diagnose participants. Anemia status was defined as a binomial variable and was
assessed at two time points, pre-COVID diagnosis and post-COVID diagnosis. Pre-COVID anemia
was assessed by lab values taken closest to COVID diagnosis in the past 5-years excluding labs
taken within 45 days of first COVID diagnosis. Post-COVID anemia was assessed by lab values
taken at 180-days ± 30-days post diagnosis as labs were not taken at uniform intervals. For
individuals with multiple Hgb labs taken within the 180-day ± 30-day follow-up range the lab
closest to 180-days follow-up was used for anemia diagnosis.
3.3.2: Demographics
Demographic variables for age, sex, and patient race were included in this study. Age
was defined as age in years at the time of COVID-19 diagnosis. This variable was recorded as a
continuous variable and then categorized into three age groups: young adults (18-35), middle
adults (36-64), and older adults (≥65). Sex was defined as a categorical variable classified as
male or female. Patient race was also defined as a categorical variable classified into two
groups: individuals identified as Black or African American and non-Black members. KPGA
members with reported race as Native Hawaiian/Pacific Islander, American Indian/Alaskan
Native, Asian, White, or their race was unknown were categorized as non-Black.
3.3.3: Comorbidities
Comorbidities shown by previous research to be associated with risk of anemia and risk
of anemia concurrently with COVID-19 infection were assessed. This included smoking, obesity,
rheumatologic disease, kidney disease, liver disease, chronic pulmonary disease (COPD),
diabetes, hypertension, hypothyroidism, cancer, and heart disease. For each comorbidity, a
binomial variable was used to define diagnosis of the respective condition as present or not
present. Body mass index was calculated as weight (kilograms) divided by height (meters); using
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this calculation, obesity was defined according to the WHO as BMI over 30 and recorded as a
binomial variable of obese (BMI>30) or not obese (BMI≤30) (WHO, 2020). For the other
comorbidities, disease status was defined by record of diagnosis prior to COVID-19 infection in
the patients’ health records pulled from KPGA’s EMR using ICD-9 and ICD-10 diagnosis codes.
Kidney disease included any diagnosis of renal disease and renal failure. Liver disease
included diagnosis of mild, moderate, and severe liver disease. Diabetes included both type 1
and type 2 diabetes diagnosis with and without chronic complications. Hypertension included
diagnosis both with and without chronic complications. Cancer was defined as diagnosis with
any malignant cancer including leukemia and lymphoma. Heart disease included diagnosis for
congestive heart disease, congestive heart failure, peripheral vascular disorder, myocardial
infarction, pulmonary circulation disease, cerebrovascular disease, and valvular disease.
3.3.4: Hospitalization
Severity of COVID-19 infection was assessed using incident hospitalization status and
was defined as a binomial categorical variable. The treatment of COVID-19 on an inpatient basis
was categorized as a hospitalization regardless of hospitalization length of stay. Any member
with an in-patient hospitalization from January 2020 through end of follow-up with a COVID-19
diagnosis code was categorized as ‘hospitalized’. Treatment for COVID-19 on an outpatient
basis was categorized as non-hospitalization.
3.4: Analysis
Baseline descriptive statistics on the demographics and other variables of interest were
conducted on the entire study population as well as a comparative breakdown and statistical
analysis of these descriptive statistics by anemia diagnosis. For the comparative analysis, chisquare tests were used for categorical variables and a pooled test was used for average preCOVID Hgb levels; the p-values for each were reported. All subsequent analysis was conducted
using a 95% confidence interval in determining statistical significance at level p-value equals
0.05. SAS version 9.4 was used to conduct the analysis.
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3.4.1: Univariate Analysis
To begin the analysis, the association between risk of anemia and each variable of
interest that were found to be significant in baseline comparative analysis or were thought to
have pathological significance were assessed. This included age, sex, patient race, smoking,
obesity, rheumatologic disease, kidney disease, liver disease, COPD, diabetes, hypertension,
hypothyroidism, cancer, heart disease, hospitalization, Hgb level pre-COVID, and anemia
diagnosis pre-COVID. Univariate logistic regression using the proc logit function in SAS was used
to assess their association with the prevalence of anemia 180-days post-COVID diagnosis. These
models were used to estimate Odds ratios and 95% confidence intervals (95% CI) for each
variable. Those with an estimated 95% CI not containing 1 and a p-value less than 0.05 were
determined to be significant.
3.4.2: Multivariable Analysis
Variables found to be significantly associated with the risk of anemia in the univariate
models were included in fitting a multivariable logistic regression to assess the risk of anemia
accounting for other variables and potential covariates. A multivariable modeling in stages
approach was used to build and fit the final model. In this approach, models were built in five
steps for each grouping of variables of interest (demographics, comorbidities, pre-COVID
anemia, and hospitalization) and assessing hospitalization as an effect modifier. Following
fitting Model 1, in each subsequent model variables from previous models were kept constant
and the new variables of interest were added and their significance to the model was assessed.
Each model was fit using backwards selection where new variables showing significant
association (p< 0.05) were kept in the final models of each stage. Model 1 was fit with the
demographic variables age, sex, and race. Model 2, Model 3, and Model 4 added comorbidities
of interest, pre-COVID anemia diagnosis, and hospitalization to the regression respectively.
Model 5 was a sensitivity analysis adding hospitalization as a potential effect modifier into the
model. Before interaction terms for hospitalization were incorporated, its impact as an effect
modifier on the relationship between post-COVID anemia and the exposure variables in Model
4 were assessed. This was done by calculating the crude and stratified odds ratios for each
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exposure. Hospitalization interaction terms for each variable it was shown to interact with were
added to the model; backwards selection was again used to fit the final model. The regression
coefficients in the final model were used to calculate odds ratios and assess the association
between risk of anemia and the variables of interest estimating risk and determining if they
were independently associated when accounting for possible confounders and other risk
factors.
We then assessed the effect modification hospitalization had on our multivariable
model. To do this we created two models that included age, sex, Black/African American race,
kidney disease, diabetes, cancer, and pre-COVID anemia. The first model, Model 6 only included
individuals treated for COVID-19 as outpatients. The second model, Model 7 only included
individuals treated for COVID-19 as inpatients in the analysis. These models were used to
calculate odds ratios and 95% CI to assess the association between our exposures of interest
and post-COVID anemia and how these associations may differ among those with severe and
non-severe COVID-19.
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Chapter 4
Results
4.1: Study Population
From the 18,184 participants enrolled in the KPGA’s CURE study cohort, 1,577 meet the
inclusion criteria and were included in this study. A full breakdown of the inclusion/exclusion
process of sample selection is presented in Figure 1. Descriptive statistics on the overall sample
population and the population stratified by anemia diagnosis at 180-days post-COVID diagnosis
can found in Table 1. Of the 1,577 individuals included in this study 67% were female, 52.4%
identified as Black or African American, 61.3% were 36-64 years old, 19.5% smoked, 55.8% had
a BMI ≥30 and 17.4% were hospitalized for COVID-19. Based on electronic medical records, it
was determined that at the time of COVID-19 our sample had previous diagnosis for
rheumatologic disease (11.9%), kidney disease (18.1%), liver disease (14.6%), COPD (40.0%),
diabetes (30.2%), hypertension (57.0%), hypothyroidism (11.7%), cancer (14.1%), and heart
disease (33.6%). The mean Hgb level of the sample pre-COVID was 12.92g/dL and the
prevalence of anemia pre-COVID was estimated to be 29.4%. When comparing pre- and postCOVID Hgb levels we found that at 180-days post-COVID diagnosis the mean Hgb level was
0.139g/dL lower for the overall sample population. When stratified by sex we found the mean
Hgb was 0.098g/dL and 0.223g/dL lower post-COVID for females and males, respectively. Figure
2 illustrates this trend in mean Hgb levels in the overall population and stratified by sex.
At 180-days post-COVID diagnosis, 538 (34.1%) of the 1,577 included participants
presented anemic Hgb levels. Of these individuals, 69.9% were female, 66.7% were Black or
African American race, 57.4% were aged between 36-64 years old, 19.0% smoked, 60.4% had a
BMI ≥30, 26.4% were hospitalized for COVID-19, the average Hgb level pre-COVID was
estimated to be 11.64g/dL and the prevalence of pre-COVID anemia was estimated to be
63.9%. Amoung the 1,039 individuals with normal Hgb levels at 180-days post COVID diagnoses,
65.5% were female, 45.0% were Black or African American race, 63.2% were aged between 3664 years old, 19.8% smoked, 53.4% had a BMI ≥30, 12.7% were hospitalized for COVID-19, the
average Hgb level pre-COVID was estimated to be 13.59g/dL and the prevalence of pre-COVID
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anemia was estimated to be 11.5%. The comparative analysis based on these descriptive
statistics found a significant association between post-covid anemia and age, race, COVID
hospitalization status, pre-COVID anemia, obesity, kidney disease, diabetes, hypertension,
cancer, and heart disease. A full list of the p-values for the pooled T-test comparing mean preCOVID Hgb levels and chi-square tests comparing the other variables of interest is provided in
Table 1.
4.2: Unadjusted (Univariate) Analysis
Unadjusted univariate analyses assessed the association between prevalence of anemia
180-days post COVID diagnosis and the exposure variables listed in Table 1. The full results of
this analysis are presented in Table 2 including estimated odds ratios, 95% confidence intervals,
and the p-value of the maximum likelihood estimate of each regression coefficient. Among the
demographic variables, age group and Black/African American race were significantly
associated with increased risk of anemia at 180-days post-COVID diagnosis. Compared to
individuals aged 18-35 years old, the estimated odds were insignificant for individuals 36-64
(OR=0.96, 95% CI: 0.72, 1.30) and significant for individuals ≥65 (OR=1.40, 95% CI: 1.00, 1.97)
years old. Individuals of Black or African American race had 2.457 (95% CI: 1.98, 3.06) the odds
compared to non-Black/African American individuals. Sex was not found to be statistically
significant with the odds for females being estimated as 1.22 (95% CI: 0.98, 1.53) that of males.
Among the comorbidities evaluated, obesity, kidney disease, diabetes, hypertension,
cancer, and heart disease were found to be significantly associated with anemia diagnosis at
180-days post-COVID diagnosis. The estimated odds for individuals diagnosed with these
comorbidities were the following: obesity (OR=1.33, 95% CI: 1.08, 1.64), kidney disease
(OR=2.48, 95% CI: 1.91, 3.22), diabetes (OR=2.14, 95% CI: 1.72, 2.68), hypertension (OR=1.44,
95% CI: 1.16, 1.78), cancer (OR=1.70, 95% CI: 1.28, 2.27), and heart disease (OR=1.55, 95% CI:
1.25, 1.93). Smoking (OR=0.95, 95% CI: 0.73, 1.23), rheumatologic disease (OR=1.33, 95% CI:
0.97, 1.81), liver disease (OR=0.99, 95% CI: 0.74, 1.33), COPD (OR=0.10, 95% CI: 0.81, 1.23), and
hypothyroidism (OR=0.90, 95% CI: 0.81, 1.23) were not significantly associated with anemia
diagnosis at 180-days post-COVID diagnosis.
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Both Hgb level and anemia diagnosis pre-COVID infection were significantly associated
with anemia diagnosis at 180-days post-COVID diagnosis. For every 1g/dL increase in pre-COVID
Hgb level, the estimated odds were 0.41 (95% CI: 0.37, 0.45). For individuals with anemia preCOVID, the estimated odds were 13.71 (95% CI: 10.57, 17.77) compared to those without
anemia pre-COVID. Hospitalization for treatment of COVID-19 was also significantly associated
with 180-day post-COVID anemia. Individuals hospitalized had an estimated odds ratio of 2.46
(95% CI: 1.89, 3.21) compared to individuals receiving outpatient treatment.
4.3: Multivariable (Adjusted) analysis
Multivariable analysis was done using a logistic regression built in four progressive
stages to assess the association between significant risk factors identified in the univariate
analysis and anemia diagnosis 180-days post-COVID diagnosis in which an event was defined as
anemic Hgb levels. For each model, backwards selection was used beginning with all significant
exposures for the specified phase building on the previous model. A full breakdown of the
model selection including estimated odds ratios, 95% confidence intervals, and the p-value of
the maximum likelihood estimate for each model building stage can be found in Table 3.
4.3.1: Model 1. Demographics
Model 1 assessed patient demographics including age, sex, and Black or African
American race. Age group 18-35 years old, females and individuals identifying as Black or
African American were used as reference groups. All were found to be significant in the model.
Compared to the above reference groups, the odds of anemia 180-days post-COVID was
estimated for 36-64 year olds (OR=0.96, 95% CI: 0.71, 1.30), ≥65 year olds (OR=1.63, 95% CI:
1.15, 2.32), females (OR=1.27, 95% CI: 1.01, 1.61), and Black or African Americans (OR=2.56,
95% CI: 2.05, 3.19).
Logit(π) = -1.44 – 0.04(age1) + 0.49(age2) + 0.24(sex) + 0.94(race)

4.3.2: Model 2. Demographics + Comorbidities
Model 2 assessed comorbidities building on Model 1, including age, female, Black or
African American race, obesity, kidney disease, diabetes, hypertension, cancer, and heart
23

disease in the base model for backwards selection. Individuals without a previous diagnosis for
each comorbidity were used as the reference groups. Using backwards selection, first
hypertension (p-value: 0.4364) was removed from the base model. Heart disease (p-value:
0.4362) was then removed from the subsequent model and obesity (p-value: 0.3205) was then
removed from the following model. The final Model 2 contained age, female, Black or African
American race, kidney disease, diabetes, and cancer. Compared to the above reference groups,
the odds of anemia 180-days post-COVID was estimated for 36-64 year olds (OR=0.76, 95% CI:
0.55, 1.04), ≥65 year olds (OR=0.89, 95% CI: 0.60, 1.31), females (OR=1.54, 95% CI: 1.20, 1.97),
Black or African Americans (OR=2.31, 95% CI: 1.85, 2.90), individuals with kidney disease
(OR=1.99, 95% CI: 1.47, 2.67), diabetes (OR=1.82, 95% CI: 1.42, 2.35), and cancer (OR=1.48, 95%
CI: 1.08, 2.03).
Logit(π) = -1.61 – 0.28(age1) + 0.12(age2) + 0.43(sex) + 0.84(race) + 0.69(CKD) + 0.60(DM) + 0.39(C)

4.3.3: Model 3. Demographics + Comorbidities + Pre-COVID Anemia
Model 3 assessed pre-COVID anemia diagnosis building on Model 2, including age, sex, Black or
African American race, kidney disease, diabetes, cancer, and pre-COVID anemia diagnosis in the
base model. Individuals without anemia pre-COVID were used as the reference group. We
found that pre-COVID anemia diagnosis was significant in the model with a maximum likelihood
estimate p-value of <.0001. Compared to the above reference groups, the odds of anemia 180days post-COVID was estimated for 36-64 year olds (OR=0.75, 95% CI: 0.52, 1.08), ≥65 year olds
(OR=0.90, 95% CI: 0.57, 1.42), females (OR=1.18, 95% CI: 0.89, 1.57), Black or African American
adults (OR=1.73, 95% CI: 1.34, 2.25), individuals with kidney disease (OR=1.48, 95% CI: 1.05,
2.10), diabetes (OR=1.60, 95% CI: 1.19, 2.14), cancer (OR=1.55, 95% CI: 1.08, 2.24), and anemia
pre-COVID (OR=11.60, 95% CI: 8.88, 15.16).
Logit(π) = -2.01 - 0.29(age1) - 0.10(age2) + 0.16(sex) + 0.55(race) + 0.39(CKD) + 0.479(DM) + 0.44(C) +2.45(Hgb)

4.3.4: Model 4. Demographics + Comorbidities + Pre-COVID Anemia + Hospitalization
Model 4 assessed hospitalization as a proxy for COVID-19 disease severity building on
Model 3 to create our final fitted model. Age, sex, Black or African American race, kidney
disease, diabetes, cancer, pre-COVID anemia diagnosis, and hospitalization were included in the
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base model. Individuals treated on an outpatient bases (non-severe COVID) were used as the
reference group. We found that hospitalization was significant in the model with a maximum
likelihood estimate p-value of 0.002 and included it in our final fitted multivariable logistic
regression model. In this final fitted model, Black or African American race (OR=1.74, 95% CI:
1.34, 2.26), diabetes (OR=1.53, 95% CI: 1.14, 2.05), cancer (OR=1.47, 95% CI: 1.02, 2.13), preCOVID anemia (OR=11.58 95% CI: 8.85, 15.17), and hospitalization (OR=1.92, 95% CI: 1.37, 2.70)
were found to be significantly associated with risk of anemia 180-days post-COVID diagnosis.
Age 36-34 years (OR=0.72, 95% CI: 0.50, 1.05), age ≥65 years (OR= 0.81, 95% CI: 0.51, 1.28),
female sex (OR=1.20, 95% CI: 0.90, 1.60), and kidney disease (OR=1.33, 95% CI: 0.93, 1.90) were
not found to be significantly associated with risk of anemia 180-days post-COVID diagnosis.
Logit(π) = -2.05 - 0.32(age1) - 0.21(age2) + 0.18(sex) + 0.55(race) + 0 .29(CKD) + 0.42(DM) + 0.39(C) + 2.45(Hgb) + 0.65(hosp)

4.3.5: Model 5. Sensitivity Analysis with Interaction Between member Race & Hospitalization
Hospitalization for COVID-19 was assessed as a potential effect modifier for the
relationship between post-COVID anemia and our exposures of interest in Model 4. A
significant interaction was found, and hospitalization was determined to be an effect modifier
on post-COVID anemia for age, sex, Black or African American race, kidney disease, diabetes,
and pre-COVID anemia diagnosis. A full presentation of the crude and stratified odds ratios
used to make this determination for each exposure can be found in Table 4.
Model 5 conducted a sensitivity analysis in which hospitalization was assessed as an
effect modifier using our final multivariable logistic regression, Model 4. This analysis included
interaction terms on hospitalization for age, female, Black or African American race, kidney
disease, diabetes, and pre-COVID anemia diagnosis in the base model. Using backwards
selection, the interaction terms between hospitalization and kidney disease (p-value: 0.7207),
diabetes (p-value: 0.4589), pre-COVID anemia (p-value: 0.1873), age (p-value: 0.1915), and
female (p-value: 0.0776) were removed from the base and subsequent models respectively. The
interaction term for hospitalization and patient race (p-value: 0.0185) was found to be
significant and included in Model 5 along with all the variables included in Model 4. From this
sensitivity analysis we found that when stratified by hospitalization, Black or African American
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race was significantly associated with risk of post-COVID anemia among (non-severe COVID
cases) outpatients (OR=2.03, 95% CI: 1.51, 2.72) but not among (severe COVID cases) inpatients
(OR=0.94, 95% CI: 0.53, 1.67). In this sensitivity analysis, self-reported race, diabetes, cancer,
pre-COVID anemia, hospitalization, and the interaction between hospitalization and selfidentified race were found to be significantly associated with anemia 180-days post-COVID
diagnosis. The estimated odds ratios were as follows: Black or African American race (OR=2.03,
95% CI: 1.52, 2.71), diabetes (OR=1.53, 95% CI: 1.14, 2.06), cancer (OR=1.45 (95% CI: 1.00,
2.10), pre-COVID anemia (OR=11.62, 95% CI: 8.87, 15.23), and hospitalization (OR=2.93, 95% CI:
1.80, 4.77). Age 36-34 years (OR=0.71, 95% CI: 0.49, 1.04), age ≥65 years (OR= 0.81, 95% CI:
0.51, 1.28), female sex (OR=1.21, 95% CI: 0.91, 1.61), and kidney disease (OR=1.36, 95% CI:
0.96, 1.94) were not found to be significant in this sensitivity analysis.
Logit(π) = -2.15 – 0.33(age1) - 0.21(age2) + 0.19(sex) + 0.71(race) + 0.31(CKD) + 0.43(CA) + 2.45(Hgb) + 1.08(hosp) - 0.77(race*hosp)

4.3.6: Model 6. & 7. Effect Modification of Hospitalization
Models 6 and 7 assessed the relationship between age, sex, Black/African American
race, kidney disease, diabetes, cancer, pre-COVID anemia and post-COVID anemia among
individuals with non-severe and severe cases of COVID-19 respectively. Each model was fit
using those without or with an incident COVID-19 hospitalization as the sample in the model.
For both models, individuals aged 18-35, females, individuals identified as Black/African
American race, those with diagnosis for kidney disease, diabetes, cancer, and pre-COVID
anemia were used as reference groups. The full results of these analysis can be seen in Table 5.
Among individuals with non-severe COVID (treated on outpatient basis) we found that
female sex (OR = 1.40; 95% CI: 1.01, 1.96), Black/African American race (OR = 2.07; 95% CI:
1.55, 2.78), diabetes (OR = 1.44; 95% CI: 1.02, 2.03), and pre-COVID anemia (OR = 10.76; 95%
CI: 8.00, 14.47) were significantly associated with increased risk of anemia at 180-days postCOVID diagnosis. Age group 36-64 as found to be a protective factor (OR = 0.67; 95% CI: 0.46,
0.99). Kidney disease (OR = 1.32; 95% CI: 1.02, 2.03) and cancer (OR = 1.53; 95% CI: 0.98, 2.37)
were found to not be significant predictors of anemia 180-days post-COVID anemia.
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Among individuals with severe COVID (treated on outpatient basis) we found that preCOVID anemia (OR = 17.67; 95% CI: 8.73, 35.79) was significantly associated with increased risk
of post-COVID anemia. Age group 36-64 (OR = 2.01; 95% CI: 0.47, 8.53), ≥65 (OR = 1.52; 95% CI:
0.34, 6.74), female sex (OR = 0.76; 95% CI: 0.41, 1.39), Black/African American race (OR = 0.88;
95% CI: 0.47, 1.64), kidney disease (OR = 1.52; 95% CI: 0.77, 2.98), and cancer (OR = 1.27; 95%
CI: 0.63, 2.56) were found not to be significant predictors of post-COVID anemia. While it did
not meet the significance threshold, diabetes (OR = 1.82; 95% CI: 0.99, 3.36) was very close and
could still be a significant predictor.
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Chapter 5
Discussion and Conclusion
5.1: Discussion
The aim of this research was to assess the prevalence of anemia in adults (≥18 years)
180-days after COVID-19 infection and potential risk factors contributing to the prevalence of
post-COVID anemia. This study also examined blood Hgb level as a potential biological pathway
explaining the persistent symptoms following COVID-19 infection known as “long-COVID”.
According to the WHO, the public health significance of anemia prevalence is categorized as
normal (≤4.9%), mild (5.0 – 19.9%), moderate (20.0 – 39.9%) and severe (≥40.0%) significance
(Le, 2016). In this study population the prevalence of anemia at 180-days post-COVID was
estimated to be 34.1% (n=538), 344 had pre-COVID anemia and 142 were hospitalized with
COVID-19. Thus, the prevalence of anemia we are seeing post-COVID represents a serious
public health concern and garners the attention of this and future research. The following
sections look at the significant results and subsequent implications of this study’s findings.
5.1.1: Significant Findings
5.1.1.1: Demographics
The first research question set out to examine if demographic factors such as age, sex,
and Black or African American race were associated with the prevalence of anemia at 180-days
post-COVID infection. In this study’s sample, we estimated that the prevalence of anemia was
32.8%, 32.0%, and 40.7% for individuals aged 18-35, 36-64, and 65 years or older respectively.
When age was evaluated alone, it was found to be significantly associated with post-COVID
anemia. Induvials 65 years or older in this sample are estimated to have 1.4 times the odds of
post-COVID anemia compared to 18-35 year olds; and we can say with 95% certainty that the
true population odds falls between 1.001 and 1.969. This follows what previous research has
shown with multiple studies finding that the risk of anemia across individuals’ lifetime is highest
at infancy and as we age into older adulthood (Chaparro & Suchdev, 2019; Wouters et al.,
2018). However, in our final adjusted multivariable model, age was not found to not be a
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significant risk factor after controlling for sex, Black or African American race, kidney disease,
diabetes, cancer, pre-COVID anemia diagnosis, and hospitalization.
The relationship between female sex and post-COVID anemia was found to not be
significant when evaluated both alone and in our final adjusted multivariable model. The
prevalence of post-COVID anemia was estimated to be 35.6% for females and 31.2% for males.
This deviates from previous research which has shown females, specifically those of
reproductive years are at higher risk of anemia compared to males as menstruation and
increased blood production during pregnancy can lead to lower blood Hgb levels (American
Society of Hematology, 2022; Chaparro & Suchdev, 2019).
Black or African American race, compared to non-Black race, was shown to be
significantly associated with post-COVID anemia when evaluated alone and in our final adjusted
multivariable model. Individuals who identify as Black or African American in our sample were
at increased risk when compared to individuals identifying as any other race or of unknown
race. When evaluated alone, it was estimated that Black/African American individuals had
2.457 times the odds of post-COVID anemia compared to non-Black individuals. We can say
with 95% confidence that the true population odds fall between 1.98 and 3.05. When
controlling for age, sex, kidney disease, diabetes, cancer, pre-COVID anemia diagnosis, and
hospitalization, we estimated that Black/African American adults in this sample had 1.74 times
the odds of post-COVID anemia and can say with 95% confidence that the true population odds
fall between 1.34 and 2.26. These results are consistent with current literature that has shown
that individuals identifying as non-Hispanic Blacks have lower Hgb levels and higher risk of
developing anemia (Chaparro & Suchdev, 2019; Gonzalez-Velez et al., 2020; Le, 2016; Weyand
et al., 2021). For instance, a study of NHANES data from 2003-2012 found that among all age
groups non-Hispanic Black adults had the highest prevalence of anemia (Le, 2016).
5.1.1.2: Comorbidities
The second research question sought to assess if specific comorbidities were associated
with the prevalence of anemia 180-days post-COVID diagnosis. In this evaluation, we found that
individuals diagnosed with kidney disease, diabetes, or cancer had significantly higher risk of
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post-COVID anemia when evaluated both alone and controlling for patient demographics.
When evaluated alone, we estimated that individuals diagnosed with kidney disease, diabetes
and cancer had an estimated 2.48, 2.14, and 1.70 times the odds of their undiagnosed
counterparts respectively. In our final fitted multivariable model controlling for age, sex, race,
pre-COVID anemia diagnosis, hospitalization and other comorbidities, diagnosis with diabetes
or cancer was associated with significantly higher risk of post-COVID anemia. We estimated that
compared to those without a diagnosis, individuals with diabetes had 1.53 times the odds of
post-COVID anemia and can say with 95% certainty that the true population odds fall between
1.14 and 2.05. Individuals with a previous cancer diagnosis were estimated to have 1.47 times
the odds of post-COVID anemia compared to those without a diagnosis, and we are 95%
confident that the true population odds are between 1.02 and 2.13. While kidney disease was
not found to be significant, it was very close to the significance threshold, with those diagnosed
with kidney disease having an estimated 1.33 times the odds of those not diagnosed, with a
95% confidence interval between 0.93 and 1.90. We also found that when evaluated alone
smoking, rheumatologic disease, liver disease, COPD, and hypothyroidism were not significantly
associated with post-COVID anemia. During model building controlling for other significant
comorbidities and demographic characteristics, obesity, hypertension, and heart disease were
not found to be significant and excluded from the final model.
The findings both support and deviate slightly from what we expected to see. Previous
literature has shown that chronic disease comorbidities such as rheumatological diseases,
kidney disease, cancer, liver disease, thyroid disease, obesity and smoking have been shown to
increase one’s risk of anemia (Chaparro & Suchdev, 2019; American Society of Hematology,
2022; Paramastri et al., 2021; Wouters et al., 2018). In this sample, we found that only diabetes
and cancer were significantly associated with post-COVID anemia in our final model. One
reason for this may be that compared to other studies, we included more potential risk factors
and applied multivariable analysis in our assessment of significant association.
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5.1.1.3: Pre-COVID Anemia Diagnosis
When examining pre-COVID anemia diagnosis we found that it was significantly
associated with post-COVID anemia. The estimated prevalence of post-COVID anemia was
74.3% and 17.4% among those with and without a pre-COVID anemia diagnosis respectively.
We estimate that the odds of post-COVID anemia for individuals with pre-COVID anemia are
11.58 times the odds of individuals without pre-COVID anemia when controlling for age, sex,
race, kidney disease, diabetes, cancer, and hospitalization. We can say with 95% confidence
that the true population odds fall between 8.85 and 15.17. This is expected as individuals with
anemia pre-COVID are more likely to continue to have anemia post-COVID. However, this may
be an over estimation as we used the most recent Hgb lab pre-COVID for Pre-COVID anima
diagnosis. Blood Hgb level is subject to variability and individuals having Hgb labs collected may
be more likely to present anemic levels as labs are more likely to be taken if the individual is ill.
5.1.1.4: Severity of COVID-19 Infection (Hospitalization)
Research question three set out to assess how severity of COVID-19 infection evaluated
by hospitalization for COVID-19 impacted the risk of post-COVID anemia. The prevalence of
post-COVID anemia in our sample population was estimated at 51.8% and 30.4% for those
treated in an inpatient and outpatient capacity, respectively. We found that individuals
hospitalized for COVID-19 were at increased risk for post-COVID anemia, and this association
was significant when evaluated alone as well as in our final fitted multivariable model. When
controlling for age, sex, race, kidney disease, diabetes, cancer, and pre-COVID anemia
diagnosis, we estimate that individuals hospitalized (with severe COVID-19) have 1.92 the odds
of post-COVID anemia compared to those not hospitalized (with less severe COVID-19). We can
say with 95% confidence that the true population odds fall between 1.37 and 2.70. These
findings support what previous research has found, with multiple studies finding that anemia is
an independent risk factor for severity of COVID-19 (Tao et al., 2020; Fouad et al., 2021;
Hariyanto & Kurniawan, 2020).
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5.1.1.5: Effect Modification of Severity of COVID-19 Infection (Hospitalization)
Hospitalization was found to be an effect modifier for the unadjusted association
between post-COVID anemia and age, sex, race, kidney disease, diabetes, and pre-COVID
anemia. However, in our sensitivity analysis when controlling for the other variables in our final
multivariable model only, the interaction on post-COVID anemia and race was found to be
significant and included in our fitted model. Among individuals treated for COVID-19 on an
outpatient basis, those identifying as Black or African American had significantly increased risk
of post-COVID anemia, with an estimated 2.03 times the odds of other races and a 95%
certainty that the true population odds fall between 1.804 and 2.72. Among individuals treated
on an inpatient bases for COVID-19, Black or African American race was not significantly
associated with post-COVID anemia. In this sample race seems to only play a significant role in
non-hospitalized (non-severe) COVID-19 cases.
When we stratified our multivariable model by hospitalization status, we found that
among individuals with non-severe COVID (outpatient treatment) the predictors identified in
our multivariate analysis play a much more significant role in predicting post-COVID anemia.
Most predictors, excluding kidney disease and cancer, were found to significantly predict postCOVID anemia risk as compared to only pre-COVID anemia predicting post-COVID anemia risk
among those with severe COVID (inpatient treatment). The severity of COVID acts as an effect
modifier on the relationship between our exposures of interest, excluding pre-COVID anemia
and post-COVID anemia. The results tell us that the risk factors of interest play a larger role in
predicting post-COVID anemia among non-severe cases of COVID-19. It is also important to
note that we had a relatively small sample size of individuals with severe COVID-19
(hospitalized) the limited statistical power may also play a factor in why the other identified risk
factors were not associated with post-COVID anemia in this subpopulation. As well as the
findings that Black/African American race was only found to be a significant risk factor among
outpatients.
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5.1.2: Implications
Current literature has shown that older individuals, females, those hospitalized for
COVID-19, diagnosed with a higher number of comorbidities like hypertension, obesity, and
immunosuppressive conditions have higher risk for long-COVID (Crook et al., 2021; Mandal et
al., 2020; Raveendran et al., 2021). Multiple studies have identified that older individuals,
females, and those diagnosed with chronic conditions such as rheumatoid diseases, other
autoimmune disease, kidney disease, cancer, liver disease, HIV, tuberculosis, thyroid disease,
inflammatory bowel disease, and obesity have increased risk of developing anemia (Chaparro &
Suchdev, 2019; American Society of Hematology, 2022). In our multivariable analysis, we found
that individuals identifying as Black or African American, those with cancer or diabetes, and
hospitalized individuals were at increased risk of post-COVID anemia. For individuals identifying
as Black or African American, this increased risk was significant among individuals (with nonsevere COVID) treated in an outpatient setting. We see significant overlap in the risk factors
identified in this study and for those of anemia and long-COVID, signifying that abnormally low
Hgb levels post-COVID may be associated with the development of long-COVID. The
implications of the findings of this study include the need for providers to closely evaluate and
develop treatment plans to reduce the high-risk individuals identified in our multivariable
analysis. Future research should evaluate the causal link between abnormal Hgb levels postCOVID and development of long-COVID including socioeconomic factors, severity of anemia,
and long-COVID diagnosis in the evaluation.
5.2: Strengths and Limitations
The strengths of this study include the long follow-up time used to assess post-COVID
anemia. Most studies evaluating the long-term implication of COVID-19 only have followed
individuals up to three or six months. The longer follow up time provides a more complete
picture of recovery from COVID-19. The fact that data on our exposure and outcome of interest
was pulled directly from participants EMR eliminates recall bias and increases the validity of the
results. Additionally, the design of this study allowed us to account for multiple exposures and
fit a multivariable model that more accurately captured the true risk of post-COVID anemia
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compared to current literature that has mainly looked at Hgb levels as an exposure and not the
outcome of interest.
This research study does have several limitations. The first limitation is the small sample
size, and the small number of individuals with Hgb labs at the 180-day follow-up period in the
overall CURE cohort reduces the statistical power and generalizability as those with labs at 180days may differ from those without. Our sample also had a small percentage of Asian, Hispanic,
and other race/ethnicity groups that may limit generalizability. Additionally, we were not able
to include socioeconomic variables in our analysis which may have also influenced the
associations evaluated. Future research could include the CDCs social vulnerability index to
account for this important exposure. Lastly, labs were not collected at uniform times for each
individual and only collected for individuals who had an appointment where labs were done in
the follow up period. In the same vein pre-COVID anemia was determined from most recent
Hgb labs to diagnosis. Individuals having labs done could be sick or at higher risk compared to
those not receiving labs leading to a possible overestimation of pre- and post-COVID anemia
prevalence. Future research could design a study in which they are not reliant on secondary
data for these diagnoses. Implementing procedure in which labs are collected at a uniform time
for all participants and health status at these times is assessed and recorded. This would also
address the sample size limitation ensuring a smaller number of participants would need to be
excluded due to missing follow up labs.
5.3 Conclusion
The results of this study add to the small but growing body of literature concerning longCOVID and its biological mechanisms. 34.1% of individuals diagnosed with COVID-19 had
anemic Hgb levels at 180-days post-COVID diagnosis. When assessing potential risk factors, we
found that individuals identifying as Black or African American had significantly higher risk of
post-COVID anemia specifically in the outpatient (non-severe COVID-19) population.
Additionally, we found that individuals diagnosed with cancer, diabetes or hospitalized (severe
COVID-19) with COVID-19 also had significantly higher risk of post-COVID Anemia. Future
research should evaluate if socioeconomic factors and severity of anemia play a role in this
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relationship as well as evaluate the prevalence of long-COVID in this population to further
evaluate if abnormally low Hgb levels play a causative role in the development of long-COVID.

35

REFERENCES
Abdo, N., Douglas, S., Batieha, A., Khader, Y., Jaddou, H., Al-Khatib, S., El-Khatib, M., AbuZaid,
H., & Ajlouni, K. (2019). The prevalence and determinants of anaemia in Jordan. Eastern
Mediterranean Health Journal, 25(5), 341–349. https://doi.org/10.26719/emhj.18.047
Amawi, H., Abu Deiab, G. I., a Aljabali, A. A., Dua, K., & Tambuwala, M. M. (2020). COVID-19
pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential
vaccines and therapeutics. Therapeutic Delivery, 11(4), 245–268.
https://doi.org/10.4155/tde-2020-0035
American Society of Hematology. (2022). Anemia. Hematology.Org.
https://www.hematology.org/education/patients/anemia
Ayoubkhani, D., Khunti, K., Nafilyan, V., Maddox, T., Humberstone, B., Diamond, I., & Banerjee,
A. (2021). Post-covid syndrome in individuals admitted to hospital with covid-19:
retrospective cohort study. BMJ, n693. https://doi.org/10.1136/bmj.n693
Barriteau, C. M., Bochey, P., Lindholm, P. F., Hartman, K., Sumugod, R., & Ramsey, G. (2020).
Blood transfusion utilization in hospitalized COVID ‐19 patients. Transfusion.
https://doi.org/10.1111/trf.15947
Bellmann-Weiler, R., Lanser, L., Barket, R., Rangger, L., Schapfl, A., Schaber, M., Fritsche, G.,
Wöll, E., & Weiss, G. (2020). Prevalence and Predictive Value of Anemia and
Dysregulated Iron Homeostasis in Patients with COVID-19 Infection. Journal of Clinical
Medicine, 9(8), 2429. https://doi.org/10.3390/jcm9082429
Benoit, J. L., Benoit, S. W., Oliveira, M. H. S., Lippi, G., & Henry, B. M. (2020). Anemia and
COVID‐19: A prospective perspective. Journal of Medical Virology, 93(2), 708–711.
https://doi.org/10.1002/jmv.26530
Bergamaschi, G., Borrelli De Andreis, F., Aronico, N., Lenti, M. V., Barteselli, C., Merli, S.,
Pellegrino, I., Coppola, L., Cremonte, E. M., Croce, G., Mordà, F., Lapia, F., Ferrari, S.,
Ballesio, A., Parodi, A., Calabretta, F., Ferrari, M. G., Fumoso, F., Gentile, A., . . . Stefani,
D. (2021). Anemia in patients with Covid-19: pathogenesis and clinical significance.
Clinical and Experimental Medicine, 21(2), 239–246. https://doi.org/10.1007/s10238020-00679-4
36

Berzuini, A., Bianco, C., Migliorini, A., Maggioni, M., Valenti, L., & Prati, D. (2020). Red blood cell
morphology in patients with COVID-19-related anemia. Blood Transfus, 19, 34–36.
https://doi.org/10.2450/2020.0242-20
Cappellini, M. D., Musallam, K. M., & Taher, A. T. (2019). Iron deficiency anaemia revisited.
Journal of Internal Medicine, 287(2), 153–170. https://doi.org/10.1111/joim.13004
Cavezzi, A., Troiani, E., & Corrao, S. (2020). COVID-19: Hemoglobin, Iron, and Hypoxia beyond
Inflammation. A Narrative Review. Clinics and Practice, 10(2), 1271.
https://doi.org/10.4081/cp.2020.1271
CDC. (2020, February 11). COVID-19 Overview and Infection Prevention and Control Priorities in
non-U.S. Healthcare Settings. Centers for Disease Control and Prevention.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/non-ussettings/overview/index.html#:%7E:text=The%20estimated%20incubation%20period%2
0is,symptoms%20or%20feel%20ill
Chaparro, C. M., & Suchdev, P. S. (2019). Anemia epidemiology, pathophysiology, and etiology
in low‐ and middle‐income countries. Annals of the New York Academy of Sciences.
https://doi.org/10.1111/nyas.14092
Crook, H., Raza, S., Nowell, J., Young, M., & Edison, P. (2021). Long covid—mechanisms, risk
factors, and management. BMJ, n1648. https://doi.org/10.1136/bmj.n1648
di Toro, A., Bozzani, A., Tavazzi, G., Urtis, M., Giuliani, L., Pizzoccheri, R., Aliberti, F., Fergnani, V.,
& Arbustini, E. (2021). Long COVID: long-term effects? European Heart Journal
Supplements, 23(Supplement_E), E1–E5. https://doi.org/10.1093/eurheartj/suab080
Faghih Dinevari, M., Somi, M. H., Sadeghi Majd, E., Abbasalizad Farhangi, M., & Nikniaz, Z.
(2021). Anemia predicts poor outcomes of COVID-19 in hospitalized patients: a
prospective study in Iran. BMC Infectious Diseases, 21(1).
https://doi.org/10.1186/s12879-021-05868-4
Fouad, S. H., Allam, M. F., Taha, S. I., Okba, A. A., Hosny, A., Moneer, M., & Roman, S. W. (2021).
Comparison of hemoglobin level and neutrophil to lymphocyte ratio as prognostic
markers in patients with COVID-19. Journal of International Medical Research, 49(7),
030006052110301. https://doi.org/10.1177/03000605211030124
37

Garg, P., Arora, U., Kumar, A., Malhotra, A., Kumar, S., Garg, S., Arora, M., Sarda, R., & Wig, N.
(2021). Risk factors for prolonged fatigue after recovery from COVID‐19. Journal of
Medical Virology, 93(4), 1926–1928. https://doi.org/10.1002/jmv.26774
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A.,
Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M. E., Katsaounou, P., Ntaganou,
M., Kyriakopoulou, M., Dimopoulos, G., Koutsodimitropoulos, I., Velissaris, D.,
Koufargyris, P., Karageorgos, A., Katrini, K., Lekakis, V., . . . Koutsoukou, A. (2020).
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.
Cell Host & Microbe, 27(6), 992–1000.e3. https://doi.org/10.1016/j.chom.2020.04.009
Gonzalez‐Velez, M., Mead‐Harvey, C., Kosiorek, H. E., Kusne, Y. N., Rivera, C., Bojanini, L.,
Northfelt, D. W., & Padrnos, L. J. (2020). Racial/ethnic differences in patients with
anemia and folate deficiency. International Journal of Laboratory Hematology, 42(4),
403–410. https://doi.org/10.1111/ijlh.13205
Hariyanto, T. I., & Kurniawan, A. (2020). Anemia is associated with severe coronavirus disease
2019 (COVID-19) infection. Transfusion and Apheresis Science, 59(6), 102926.
https://doi.org/10.1016/j.transci.2020.102926
Harrison, A. G., Lin, T., & Wang, P. (2020). Mechanisms of SARS-CoV-2 Transmission and
Pathogenesis. Trends in Immunology, 41(12), 1100–1115.
https://doi.org/10.1016/j.it.2020.10.004
Le, C. H. H. (2016). The Prevalence of Anemia and Moderate-Severe Anemia in the US
Population (NHANES 2003–2012). PLOS ONE, 11(11), e0166635.
https://doi.org/10.1371/journal.pone.0166635
Lee, J. O., Lee, J. H., Ahn, S., Kim, J. W., Chang, H., Kim, Y. J., Lee, K. W., Kim, J. H., Bang, S. M., &
Lee, J. S. (2014). Prevalence and Risk Factors for Iron Deficiency Anemia in the Korean
Population: Results of the Fifth Korea National Health and Nutrition Examination Survey.
Journal of Korean Medical Science, 29(2), 224.
https://doi.org/10.3346/jkms.2014.29.2.224
Mandal, S., Barnett, J., Brill, S. E., Brown, J. S., Denneny, E. K., Hare, S. S., Heightman, M.,
Hillman, T. E., Jacob, J., Jarvis, H. C., Lipman, M. C. I., Naidu, S. B., Nair, A., Porter, J. C.,
38

Tomlinson, G. S., & Hurst, J. R. (2020). ‘Long-COVID’: a cross-sectional study of persisting
symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19.
Thorax, 76(4), 396–398. https://doi.org/10.1136/thoraxjnl-2020-215818
Martinsson, A., Andersson, C., Andell, P., Koul, S., Engström, G., & Smith, J. G. (2014). Anemia in
the general population: prevalence, clinical correlates and prognostic impact. European
Journal of Epidemiology, 29(7), 489–498. https://doi.org/10.1007/s10654-014-9929-9
Mohamed Khosroshahi, L., Rokni, M., Mokhtari, T., & Noorbakhsh, F. (2021). Immunology,
immunopathogenesis and immunotherapeutics of COVID-19; an overview. International
Immunopharmacology, 93, 107364. https://doi.org/10.1016/j.intimp.2020.107364
Paramastri, R., Hsu, C. Y., Lee, H. A., & Chao, J. (2021). Interactions of Lifestyle Factors on the
Risk of Anemia Among Taiwanese Adults. Current Developments in Nutrition,
5(Supplement_2), 1004. https://doi.org/10.1093/cdn/nzab052_007
Pasini, E., Corsetti, G., Romano, C., Scarabelli, T. M., Chen-Scarabelli, C., Saravolatz, L., &
Dioguardi, F. S. (2021). Serum Metabolic Profile in Patients With Long-Covid (PASC)
Syndrome: Clinical Implications. Frontiers in Medicine, 8.
https://doi.org/10.3389/fmed.2021.714426
Raveendran, A., Jayadevan, R., & Sashidharan, S. (2021). Long COVID: An overview. Diabetes &
Metabolic Syndrome: Clinical Research & Reviews, 15(3), 869–875.
https://doi.org/10.1016/j.dsx.2021.04.007
Salian, V. S., Wright, J. A., Vedell, P. T., Nair, S., Li, C., Kandimalla, M., Tang, X., Carmona
Porquera, E. M., Kalari, K. R., & Kandimalla, K. K. (2021). COVID-19 Transmission, Current
Treatment, and Future Therapeutic Strategies. Molecular Pharmaceutics, 18(3), 754–
771. https://doi.org/10.1021/acs.molpharmaceut.0c00608
Sanyal, S. (2020). How SARS-CoV-2 (COVID-19) spreads within infected hosts — what we know
so far. Emerging Topics in Life Sciences, 4(4), 383–390.
https://doi.org/10.1042/etls20200165
Sieck, G. C. (2020). Physiology in Perspective: A Key Role of Physiology in Understanding COVID19. Physiology, 35(5), 286–287. https://doi.org/10.1152/physiol.00025.2020

39

Sonnweber, T., Boehm, A., Sahanic, S., Pizzini, A., Aichner, M., Sonnweber, B., Kurz, K.,
Koppelstätter, S., Haschka, D., Petzer, V., Hilbe, R., Theurl, M., Lehner, D., Nairz, M.,
Puchner, B., Luger, A., Schwabl, C., Bellmann-Weiler, R., Wöll, E., . . . Weiss, G. (2020).
Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving
lung pathologies and poor patients’ performance: a prospective observational cohort
study. Respiratory Research, 21(1). https://doi.org/10.1186/s12931-020-01546-2
Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P., & Diaz, J. V. (2022). A clinical case definition
of post-COVID-19 condition by a Delphi consensus. The Lancet Infectious Diseases, 22(4),
e102–e107. https://doi.org/10.1016/s1473-3099(21)00703-9
Tahaghoghi-Hajghorbani, S., Zafari, P., Masoumi, E., Rajabinejad, M., Jafari-Shakib, R., Hasani,
B., & Rafiei, A. (2020). The role of dysregulated immune responses in COVID-19
pathogenesis. Virus Research, 290, 198197.
https://doi.org/10.1016/j.virusres.2020.198197
Taneri, P. E., Gómez-Ochoa, S. A., Llanaj, E., Raguindin, P. F., Rojas, L. Z., Roa-Díaz, Z. M.,
Salvador, D., Groothof, D., Minder, B., Kopp-Heim, D., Hautz, W. E., Eisenga, M. F.,
Franco, O. H., Glisic, M., & Muka, T. (2020). Anemia and iron metabolism in COVID-19: a
systematic review and meta-analysis. European Journal of Epidemiology, 35(8), 763–
773. https://doi.org/10.1007/s10654-020-00678-5
Tao, Z., Xu, J., Chen, W., Yang, Z., Xu, X., Liu, L., Chen, R., Xie, J., Liu, M., Wu, J., Wang, H., & Liu,
J. (2020). Anemia is associated with severe illness in COVID‐19: A retrospective cohort
study. Journal of Medical Virology, 93(3), 1478–1488.
https://doi.org/10.1002/jmv.26444
Tjendra, Y., al Mana, A. F., Espejo, A. P., Akgun, Y., Millan, N. C., Gomez-Fernandez, C., & Cray,
C. (2020). Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of
Multiple Biomarkers. Archives of Pathology & Laboratory Medicine, 144(12), 1465–1474.
https://doi.org/10.5858/arpa.2020-0471-sa
Velavan, T. P., & Meyer, C. G. (2020). Mild versus severe COVID-19: Laboratory markers.
International Journal of Infectious Diseases, 95, 304–307.
https://doi.org/10.1016/j.ijid.2020.04.061
40

Weyand, A. C., & McGann, P. T. (2021). Eliminating race-based reference ranges in
haematology: a call to action. The Lancet Haematology, 8(6), e462–e466.
https://doi.org/10.1016/s2352-3026(21)00106-x
WHO. (2019, November 12). Anaemia. World Health Organization.
https://www.who.int/health-topics/anaemia#tab=tab_1
WHO. (2020, February 21). Obesity. World Health Organization. https://www.who.int/healthtopics/obesity#tab=tab_1
Wouters, H. J., van der Klauw, M. M., de Witte, T., Stauder, R., Swinkels, D. W., Wolffenbuttel,
B. H., & Huls, G. (2018). Association of anemia with health-related quality of life and
survival: a large population-based cohort study. Haematologica, 104(3), 468–476.
https://doi.org/10.3324/haematol.2018.195552
Yan, Z., Yang, M., & Lai, C. L. (2021). Long COVID-19 Syndrome: A Comprehensive Review of Its
Effect on Various Organ Systems and Recommendation on Rehabilitation Plans.
Biomedicines, 9(8), 966. https://doi.org/10.3390/biomedicines9080966
Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. Clinical
Immunology, 215, 108427. https://doi.org/10.1016/j.clim.2020.108427

41

APPENDIX
Figure 1. Application of inclusion/exclusion criteria selecting final sample from KPGA CURE cohort to
evaluate the presence of anemia, measure by hemoglobin (Hgb), 180-days post-COVID-19 infection
(sample population).
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lab 180‐days post‐COVID
(n 14,980)
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(n 213)
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(n 1,577)
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Table 1. Study population descriptive statistics at the time of COVID-Diagnosis, January 2020 – July 2021

Variable

Sample Population

Anemia Diagnosis at 180-days
Post COVID

p-value*

(n=1577)
n
12.92b

%
1.74c

No
(n=1039, 65.9%)
n
%
b
13.59
1.42c

463

29.36

119

11.45

344

63.94

<.0001

274

17.37

132

12.70

142

26.39

<.0001

18-35 247
36-64 966
≥65 364

15.66
61.26
23.08

166
657
216

15.98
63.23
20.79

81
309
148

15.06
57.43
27.51

Hgb Level Pre-COVID
Diagnosis (meanb, stdc)
Pre-COVID Anemia
Diagnosis
Hospitalized for COVID

Yes
(n=538, 34.1%)
n
%
b
11.64
1.58c

<.0001

Demographics
Age Group

0.0107

Sex

0.0819
Female 1057
Male 520

67.03
32.38

681
358

65.54
34.46

376
162

69.89
30.11

Patient Race
Black 826
52.38
Non-Black 751
47.62
Comorbidities prior to COVID-19 infectiona
Smoking
308
19.53
Obesity (BMI≥30)
880
55.80
Rheumatologic Disease
188
11.92
Kidney Disease
286
18.14
Liver Disease
230
14.58
Chronic Pulmonary
631
40.01
Disease (COPD)
Diabetes
476
30.18
Hypertension
899
57.01
Hypothyroidism
184
11.67
Malignant Cancer
223
14.14
Heart Disease
530
33.61

<.0001
467
572

44.95
55.05

359
179

66.73
33.27

206
555
113
138
152
416

19.83
53.42
10.88
13.28
14.63
40.04

102
325
75
148
78
215

18.95
60.41
13.94
27.51
14.50
39.96

0.6803
0.0080
0.0750
<.0001
0.9442
0.9768

255
561
125
123
314

24.54
53.99
12.03
11.84
30.22

221
338
59
100
216

41.08
62.83
10.97
18.59
40.15

<.0001
0.0008
0.5325
0.0003
<.0001

*p-value was calculated using a pooled t-test for pre-COVID Hgb level and chi-squared test for all other
variables.
a
Comorbidities were defined using Icd-9 and ICD-10 codes if an individual were ever diagnosed prior to COVID19 infection.
b
the mean Hgb level pre-Covid for the given sample or corresponding sample subpopulation
c
the standard deviation of the mean Hgb level for the given sample or corresponding sample subpopulation
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Figure 2. Average change of hemoglobin (Hgb) levels among study population, overall and stratified by
sex. Month 0 represents the pre-COVID-19 Hgb levels
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Female Anemia dx Threshold

Table 2. Univariate analysis of exposure variables association with anemia diagnosis 180-days postCOVID diagnosis
Exposure

Odds Ratio

Hgb Level Pre-COVID
Diagnosisb (g/dL)
Pre-COVID Anemia
Diagnosis
Hospitalized for COVID*

95% Confidence Interval
p-valuea
Lower Limit
Upper Limit
0.410
0.372
0.453
<.0001
13.709

10.574

17.773

<.0001

2.464

1.891

3.210

<.0001

0.964
1.404
1.220
2.457

0.715
1.001
0.975
1.977

1.299
1.969
1.527
3.052

0.0615
0.0063
0.0821
<.0001

0.946
1.331
1.327
2.477
0.990
0.997

0.727
1.077
0.971
1.909
0.737
0.806

1.232
1.644
1.814
3.215
1.329
1.233

0.6820
0.0081
0.0756
<.0001
0.9442
0.9768

2.143
1.440
0.901
1.700
1.549

1.716
1.163
0.648
1.276
1.246

2.677
1.782
1.251
2.266
1.925

<.0001
0.0008
0.5327
0.0003
<.0001

Demographics
Age Groupc
36-64
≥65
Female
Black/African American
Race

Comorbiditiesd
Smoking
Obesity
Rheumatologic Disease
Kidney Disease
Liver Disease
Chronic Pulmonary
Disease (COPD)
Diabetes
Hypertension
Hypothyroidism
Malignant Cancer
Heart Disease
a

p-value for the regression coefficients maximum likelihood estimate
Odds ratio is expressed as odds per 1g/dL increase in Hgb lab value
c
Odds ratios calculation used age group 18-35 as the comparison group
d
Individuals without a previous diagnosis used as the comparison group in comorbidity OR calculations
b
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Table 3. Multivariable Analysis, variables included in the final fitted model of each model building stage

Exposure

Odds Ratio

95% Confidence Interval
Lower Limit

p-valuea

Upper Limit

Model 1. Patient Demographics
Age Groupb
36-64
≥65
Female
Black/African American Race

0.960
1.629
1.272
2.556

0.707
1.145
1.006
2.051

1.303
2.316
1.607
3.185

0.0123
0.0002
0.0440
<.0001

0.552
0.598
1.203
1.848
1.474
1.418
1.077

1.039
1.314
1.972
2.897
2.674
2.347
2.032

0.0845
0.5490
0.0006
<.0001
<.0001
<.0001
0.0155

1.079
1.421
1.568
2.247
2.097
2.137
2.242
15.163

0.1208
0.6576
0.2625
<.0001
0.0258
0.0017
0.0183
<.0001

Model 2. Patient Demographics + Comorbidities
Age Groupb
36-64
≥65
Female
Black/African American Race
Kidney Disease
Diabetes
Malignant Cancer

0.757
0.887
1.541
2.313
1.985
1.824
1.479

Model 3. Patient Demographics + Comorbidities + Pre-COVID Anemia
Age Groupb
36-64
≥65
Female
Black/African American Race
Kidney Disease
Diabetes
Malignant Cancer
Pre-COVID Anemia Diagnosis

0.748
0.902
1.178
1.732
1.483
1.595
1.554
11.600

0.519
0.573
0.885
1.336
1.049
1.191
1.077
8.875

Model 4d. Patient Demographics + Comorbidities + Pre-COVID Anemia + Hospitalization
Age Groupb
36-64
≥65
Female
Black/African American Race
Kidney Disease
Diabetes
Malignant Cancer
Pre-COVID Anemia Diagnosis
Hospitalizationc

0.724
0.809
1.199
1.739
1.331
1.529
1.474
11.582
1.920

0.500
0.510
0.899
1.339
0.934
1.139
1.019
8.846
1.365

1.047
1.283
1.598
2.258
1.897
2.052
2.133
15.165
2.699

0.0859
0.3673
0.2170
<.0001
0.1141
0.0047
0.0394
<.0001
0.002

Model 5e. Sensitivity Analysis with Interaction between Member Race and Hospitalization
Age Groupb
36-64
≥65
Female
Black/African American Race

0.714
0.808
1.207
2.031

0.493
0.509
0.905
1.523
46

1.035
1.284
1.610
2.708

0.0752
0.3673
0.1994
<.0001

Kidney Disease
Diabetes
Malignant Cancer
Pre-COVID Anemia Diagnosis
Hospitalizationc
Race*Hospitalization
Outpatients
Hospitalizations

1.363
1.532
1.450
11.621
2.932

0.956
1.141
1.003
8.869
1.804

1.942
2.056
2.097
15.225
4.765

0.0872
0.0046
0.0482
<.0001
<.0001

2.031
0.937

1.514
0.527

2.723
1.667

0.0185

a

p-value for the regression coefficients maximum likelihood estimate in the given model
Age group 18-35 used as the reference category for models and OR estimates
c
Individuals treated on outpatient bases used as reference group for models and OR calculations
d
Final fitted model used for the final analysis of potential risk factors and post-COVID anemia
e
Final fitted model assessing hospitalizations role as an effect modifier
b
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Table 4. Odds ratios assessing hospitalization role as an effect modifier

Exposure

Odds Ratios (95% CI)
Final Adjusted Model

Hospitalization as an
Effect Modifier,
Outpatient

Hospitalization as an
Effect Modifier,
Inpatient

Agea
36-64
≥65
Sex, Female*
Black/African American
Race*
Kidney Disease
Diabetes
Malignant Cancer*
Pre-COVID Anemia

0.724 (0.500, 1.047)
0.809 (0.510, 1.283)
1.199 (0.899, 1.598)
1.739 (1.339, 2.258)

0.860 (0.628, 1.177)
1.170 (0.799, 1.712)
0.647 (0.495, 0.845)
2.768 (2.157, 3.553)

1.070 (0.363, 3.270)
1.069 (0.353, 3.270)
1.182 (0.733, 1.907)
1.582 (0.979, 2.556)

1.331 (0.934, 1.897)
1.529 (1.139, 2.052)
1.474 (1.019, 2.133)
11.582 (8.846, 15.165)

1.845 (1.328, 2.563)
1.796 (1.384, 2.331)
1.539 (1.081, 2.190)
12.662 (9.497, 16.881)

2.669 (1.622, 4.394)
2.285 (1.408, 3.708)
1.313 (0.767, 2.245)
18.168 (9.417,35.054)

* Hospitalization acts as an effect modifier on variables relationship with 180-day post-COVID anemia
a
Age group 18-35 used as the reference group for odds ratio calculations
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Table 5. Odds ratios and 95% CI Assessing post-COVID anemia risk for Model 3 stratified by
hospitalization status

Exposure

Odds Ratio

p-valuea

95% Confidence Interval
Lower Limit

Upper Limit

Model 6. Outpatients (non-severe COVID)
Age Groupb
36-64
≥65
Female
Black/African American Race
Kidney Disease
Diabetes
Malignant Cancer
Pre-COVID Anemia Diagnosis

0.671
0.891
1.403
2.073
1.323
1.440
1.528
10.761

0.457
0.536
1.006
1.547
0.862
1.022
0.984
8.002

0.985
1.480
1.957
2.778
2.033
2.027
2.373
14.471

0.0418
0.6548
0.0463
<.0001
0.2004
0.0370
0.0592
<.0001

2.007
1.518
0.755
0.881
1.515
1.824
1.269
17.672

0.472
0.342
0.408
0.474
0.772
0.991
0.630
8.726

8.534
6.742
1.394
1.638
2.976
3.358
2.558
35.789

0.3455
0.5832
0.3684
0.6885
0.2273
0.0535
0.5047
<.0001

Model 7. Inpatients (severe COVID)
Age Groupb
36-64
≥65
Female
Black/African American Race
Kidney Disease
Diabetes
Malignant Cancer
Pre-COVID Anemia Diagnosis
a
b

p-value for the regression coefficients maximum likelihood estimate in the given model
Age group 18-35 used as the reference category for models and OR estimates
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